P09 Long-term obeticholic acid (OCA) for Primary Biliary Cholangitis (PBC) in a clinical trial improved event free survival (death, liver transplant and hepatic decompensation) compared to external controls from the GLOBAL PBC real-world database

Abstract

Background and AimsThe POISE randomized double-blind (DB) placebo-controlled trial and open label extension (OLE) demonstrated that obeticholic acid (OCA) reduced biomarkers associated with adverse clinical outcomes in patients with primary...